$CYRX
Cryoport, Inc.

2015 Q4 Form 10-Q Financial Statement

#000114420416080857 Filed on February 11, 2016

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q1 2014 Q4
Revenue $1.459M $1.198M $975.0K
YoY Change 49.64% 43.47% 28.8%
Cost Of Revenue $1.070M $830.0K $740.7K
YoY Change 44.47% 20.29% 25.48%
Gross Profit $384.0K $370.0K $235.0K
YoY Change 63.4% 158.74% 40.72%
Gross Profit Margin 26.32% 30.88% 24.1%
Selling, General & Admin $2.835M $1.980M $1.493M
YoY Change 89.95% 47.76% 14.34%
% of Gross Profit 738.38% 535.14% 635.21%
Research & Development $227.8K $90.00K $99.05K
YoY Change 129.94% 12.5% -16.4%
% of Gross Profit 59.31% 24.32% 42.15%
Depreciation & Amortization $80.00K $40.00K $50.00K
YoY Change 60.0% -20.0% -2.87%
% of Gross Profit 20.83% 10.81% 21.28%
Operating Expenses $3.063M $2.060M $1.592M
YoY Change 92.43% 45.07% 11.78%
Operating Profit -$2.679M -$1.693M -$1.357M
YoY Change 97.42% 32.89% 7.96%
Interest Expense $79.95K -$240.0K $48.61K
YoY Change 64.48% 50.0% 52.91%
% of Operating Profit
Other Income/Expense, Net -$1.347K $0.00 -$1.906K
YoY Change -29.33% -100.0%
Pretax Income -$2.760M -$1.940M -$1.408M
YoY Change 96.07% 34.72% -23.51%
Income Tax $305.00 $1.600K $0.00
% Of Pretax Income
Net Earnings -$2.760M -$1.937M -$1.408M
YoY Change 96.05% 34.42% -23.48%
Net Earnings / Revenue -189.2% -161.69% -144.41%
Basic Earnings Per Share
Diluted Earnings Per Share -$381.7K -$386.5K -$282.0K
COMMON SHARES
Basic Shares Outstanding 7.225M shares 60.06M shares 60.06M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q4 2015 Q1 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.200M $1.400M $800.0K
YoY Change 550.0% 250.0% 300.0%
Cash & Equivalents $5.247M $1.405M $773.9K
Short-Term Investments
Other Short-Term Assets $289.0K $97.34K $100.0K
YoY Change 188.97% -50.47% -2.65%
Inventory $52.88K $69.68K $100.0K
Prepaid Expenses
Receivables $616.8K $589.7K $400.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $6.206M $2.162M $1.400M
YoY Change 343.29% 94.48% 41.65%
LONG-TERM ASSETS
Property, Plant & Equipment $875.7K $307.9K $300.0K
YoY Change 191.89% -24.69% -35.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $400.0K $0.00 $0.00
YoY Change
Total Long-Term Assets $1.253M $444.7K $500.0K
YoY Change 150.51% -25.67% -24.54%
TOTAL ASSETS
Total Short-Term Assets $6.206M $2.162M $1.400M
Total Long-Term Assets $1.253M $444.7K $500.0K
Total Assets $7.459M $2.607M $1.900M
YoY Change 292.56% 52.44% 15.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.100M $800.0K $700.0K
YoY Change 57.14% 33.33% -22.22%
Accrued Expenses $400.0K $700.0K $600.0K
YoY Change -33.33% 40.0% 50.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $1.500M $300.0K
YoY Change -100.0%
Long-Term Debt Due $1.000M $0.00 $1.300M
YoY Change -23.08% -100.0% 160.0%
Total Short-Term Liabilities $2.468M $2.996M $3.000M
YoY Change -17.72% -25.36% 69.13%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.468M $2.996M $3.000M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.468M $3.023M $3.000M
YoY Change -17.72% -24.7% -1.68%
SHAREHOLDERS EQUITY
Retained Earnings -$97.77M
YoY Change 13.85%
Common Stock $114.3M $97.35M
YoY Change 16.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.990M -$416.3K -$1.100M
YoY Change
Total Liabilities & Shareholders Equity $7.459M $2.607M $1.900M
YoY Change 292.56% 52.44% 15.08%

Cashflow Statement

Concept 2015 Q4 2015 Q1 2014 Q4
OPERATING ACTIVITIES
Net Income -$2.760M -$1.937M -$1.408M
YoY Change 96.05% 34.42% -23.48%
Depreciation, Depletion And Amortization $80.00K $40.00K $50.00K
YoY Change 60.0% -20.0% -2.87%
Cash From Operating Activities -$1.400M -$1.290M -$1.070M
YoY Change 30.84% 5.74% 27.38%
INVESTING ACTIVITIES
Capital Expenditures -$370.0K $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$370.0K $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $5.000M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -40.00K 1.920M 1.730M
YoY Change -102.31% 40.15% 220.37%
NET CHANGE
Cash From Operating Activities -1.400M -1.290M -1.070M
Cash From Investing Activities -370.0K 0.000 0.000
Cash From Financing Activities -40.00K 1.920M 1.730M
Net Change In Cash -1.810M 630.0K 660.0K
YoY Change -374.24% 320.0% -320.0%
FREE CASH FLOW
Cash From Operating Activities -$1.400M -$1.290M -$1.070M
Capital Expenditures -$370.0K $0.00 $0.00
Free Cash Flow -$1.030M -$1.290M -$1.070M
YoY Change -3.74% 5.74% 27.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
981992 USD
CY2015Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
725712 USD
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1405186 USD
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
377113 USD
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
7247 USD
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
616785 USD
CY2015Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
589699 USD
CY2015Q4 us-gaap Inventory Net
InventoryNet
52880 USD
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
288965 USD
CY2015Q1 us-gaap Other Assets Current
OtherAssetsCurrent
97337 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
6206055 USD
CY2015Q1 us-gaap Assets Current
AssetsCurrent
2161902 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
875673 USD
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
307926 USD
CY2015Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
13484 USD
CY2015Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
136821 USD
CY2015Q4 us-gaap Assets
Assets
7458615 USD
CY2015Q1 us-gaap Assets
Assets
2606649 USD
CY2015Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1109243 USD
CY2015Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
758696 USD
CY2015Q1 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
976581 USD
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
5026 USD
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
114334637 USD
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-97768079 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
4990267 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7458615 USD
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2606649 USD
CY2015Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2015Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
0 USD
CY2015Q1 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
26452 USD
CY2015Q4 us-gaap Liabilities
Liabilities
2468348 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2468348 USD
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2996496 USD
CY2015Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2835372 USD
CY2014Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1492732 USD
CY2015Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
227765 USD
CY2015Q4 us-gaap Operating Expenses
OperatingExpenses
3063137 USD
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-2678855 USD
CY2015Q4 us-gaap Interest Expense
InterestExpense
79946 USD
CY2015Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1347 USD
CY2015Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2760148 USD
CY2015Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
305 USD
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-2760453 USD
CY2015Q4 us-gaap Other Preferred Stock Dividends And Adjustments
OtherPreferredStockDividendsAndAdjustments
0 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-20174 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
36430 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4336049 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2835293 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
713993 USD
CY2011Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
us-gaap Sales Revenue Net
SalesRevenueNet
4326654 USD
us-gaap Sales Revenue Net
SalesRevenueNet
2736776 USD
us-gaap Cost Of Revenue
CostOfRevenue
3018147 USD
us-gaap Cost Of Revenue
CostOfRevenue
1937926 USD
us-gaap Gross Profit
GrossProfit
1308507 USD
us-gaap Gross Profit
GrossProfit
798850 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7019500 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4431290 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
405785 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
267575 USD
us-gaap Interest Expense
InterestExpense
984748 USD
us-gaap Interest Expense
InterestExpense
1185337 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5029 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2829 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-7106555 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5088181 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3625 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1600 USD
us-gaap Net Income Loss
NetIncomeLoss
-7110180 USD
us-gaap Net Income Loss
NetIncomeLoss
-5089781 USD
us-gaap Other Preferred Stock Dividends And Adjustments
OtherPreferredStockDividendsAndAdjustments
4474348 USD
us-gaap Other Preferred Stock Dividends And Adjustments
OtherPreferredStockDividendsAndAdjustments
2961723 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
687267 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
194901 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12271795 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8246405 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.96
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.65
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6259686 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5002683 shares
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
166324 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
155226 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
417003 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1148153 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2057236 USD
us-gaap Share Based Compensation
ShareBasedCompensation
565220 USD
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-37247 USD
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-5773 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
36006 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
465 USD
us-gaap Increase Decrease In Long Term Receivables Current
IncreaseDecreaseInLongTermReceivablesCurrent
63092 USD
us-gaap Increase Decrease In Long Term Receivables Current
IncreaseDecreaseInLongTermReceivablesCurrent
-107901 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
15274 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
37255 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
350547 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
154249 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-330878 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
163348 USD
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
0 USD
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
1766997 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
3896678 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
369581 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
773922 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
67851 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-713993 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-67851 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8892281 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3307485 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
3842239 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
404341 USD
cyrx Convertible Preferred Stock Beneficial Conversion Feature And Fair Value Of Warrants Issued
ConvertiblePreferredStockBeneficialConversionFeatureAndFairValueOfWarrantsIssued
4474348 USD
cyrx Convertible Preferred Stock Beneficial Conversion Feature And Fair Value Of Warrants Issued
ConvertiblePreferredStockBeneficialConversionFeatureAndFairValueOfWarrantsIssued
2961723 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
2802854 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
10881 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
11631 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 USD
CY2015Q3 cyrx Public Offering Units Issued
PublicOfferingUnitsIssued
2090750 shares
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
50000 USD
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
212000 USD
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
72000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
9658 USD
cyrx Debt Instrument Convertible Beneficial Conversion Feature Related Party Notes Payable
DebtInstrumentConvertibleBeneficialConversionFeatureRelatedPartyNotesPayable
-521056 USD
cyrx Debt Instrument Convertible Beneficial Conversion Feature Related Party Notes Payable
DebtInstrumentConvertibleBeneficialConversionFeatureRelatedPartyNotesPayable
0 USD
cyrx Proceeds From Issuance Common Stock And Warrants Public Offering
ProceedsFromIssuanceCommonStockAndWarrantsPublicOffering
-5938099 USD
cyrx Proceeds From Issuance Common Stock And Warrants Public Offering
ProceedsFromIssuanceCommonStockAndWarrantsPublicOffering
0 USD
cyrx Proceeds From Issuance Of Common Stock Accrued Board Of Director Compensation
ProceedsFromIssuanceOfCommonStockAccruedBoardOfDirectorCompensation
54813 USD
cyrx Proceeds From Issuance Of Common Stock Accrued Board Of Director Compensation
ProceedsFromIssuanceOfCommonStockAccruedBoardOfDirectorCompensation
0 USD
cyrx Noncash Or Part Noncash Acquisition Reclassification Of Shipper Inventory To Fixed Assets
NoncashOrPartNoncashAcquisitionReclassificationOfShipperInventoryToFixedAssets
32074 USD
cyrx Noncash Or Part Noncash Acquisition Reclassification Of Shipper Inventory To Fixed Assets
NoncashOrPartNoncashAcquisitionReclassificationOfShipperInventoryToFixedAssets
0 USD
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
40600 USD
CY2015Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
12200 USD
cyrx Discount Price Per Share Percentage
DiscountPricePerSharePercentage
0.2 pure
us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
521100 USD
CY2015Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
280400 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
195600 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
43400 USD
CY2015Q4 cyrx Accrued Interest Payable
AccruedInterestPayable
0 USD
CY2015Q1 cyrx Accrued Interest Payable
AccruedInterestPayable
4600 USD
CY2015Q4 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
24700 USD
CY2015Q4 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
27600 sqft
CY2015Q4 cyrx Consulting Service Fee
ConsultingServiceFee
75000 USD
CY2014Q4 cyrx Consulting Service Fee
ConsultingServiceFee
95600 USD
cyrx Consulting Service Fee
ConsultingServiceFee
215500 USD
cyrx Consulting Service Fee
ConsultingServiceFee
257500 USD
CY2015Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
8800000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M12D
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
266100 USD
CY2015Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13920938 shares
CY2015Q1 cyrx Discount Price Per Share Percentage
DiscountPricePerSharePercentage
0.2 pure
CY2015Q4 us-gaap Deposits Assets
DepositsAssets
363403 USD
CY2015Q1 us-gaap Deposits Assets
DepositsAssets
0 USD
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7247466 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7247466 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5025577 shares
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5025577 shares
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
615000 USD
us-gaap Nature Of Operations
NatureOfOperations
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Note 2.&#160;Nature of the Business</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. The Company provides leading edge logistics solutions for biologic materials, such as immunotherapies, stem cells, CAR-T cells and reproductive cells for clients worldwide. Leading global companies, such as FedEx, UPS and DHL have each separately selected Cryoport as the preferred cryogenic logistics provider for time- and temperature-sensitive biological material. &#160;Cryoport actively&#160;supports points-of-care, contract research organizations, central laboratories, pharmaceutical companies, contract manufacturers and university researchers.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company is a Nevada corporation and its <font style="BACKGROUND-COLOR: transparent">common stock is traded on the NASDAQ Capital Market exchange under the ticker symbol &#8220;CYRX.&#8221;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i>Going Concern</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 31.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The unaudited condensed consolidated financial statements have been prepared using the accrual method of accounting in accordance with U.S. GAAP and have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. We have sustained operating losses since our inception and have used substantial amounts of working capital in our operations. At December 31, 2015, we had an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">109.4</font> million. During the nine months ended December 31, 2015, we used cash in operations of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.3</font> million and had a net loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.1</font> million.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt">We expect to continue to incur substantial additional operating losses from costs related to the commercialization and expansion of our Cryoport Express<sup style="font-style:normal">&#174;</sup></font> <font style="FONT-SIZE: 10pt">Solutions and do not expect that revenues from operations will be sufficient to satisfy our funding requirements in the near term. We believe that our cash resources at December 31, 2015, together with the revenues generated from our services will be sufficient to sustain our planned operations into the second quarter of fiscal year 2017; however, we must obtain additional capital to fund operations thereafter and for the achievement of sustained profitable operations. These factors raise substantial doubt about our ability to continue as a going concern. We are currently working on funding alternatives in order to secure sufficient operating capital to allow us to continue to operate as a going concern.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt">The level of future capital requirements will depend upon many factors, including the success of our commercialization efforts and the level of customer adoption of our Cryoport Express<sup style="font-style:normal">&#174;</sup></font> <font style="FONT-SIZE: 10pt">Solutions as well as our ability to establish additional collaborative arrangements. We cannot make any assurances that the sales ramp will lead to achievement of sustained profitable operations or that any additional financing will be completed on a timely basis and on acceptable terms or at all. Management&#8217;s inability to successfully achieve significant revenue increases or to complete any other financing will adversely impact our ability to continue as a going concern.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Use of Estimates</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company&#8217;s significant estimates include the allowance for doubtful accounts, recoverability of long-lived assets, allowance for inventory obsolescence, deferred taxes and their accompanying valuations, and valuation of equity instruments and conversion features.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1893088 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3936108 shares
cyrx Maturity Period Of Highly Liquid Investments
MaturityPeriodOfHighlyLiquidInvestments
P90D
cyrx Loss On Write Off Patents
LossOnWriteOffPatents
98086 USD
cyrx Loss On Write Off Patents
LossOnWriteOffPatents
0 USD
us-gaap Stock Issued1
StockIssued1
75075 USD
us-gaap Stock Issued1
StockIssued1
0 USD
cyrx Increase Decrease In Deposits And Other Current Assets
IncreaseDecreaseInDepositsAndOtherCurrentAssets
479956 USD
cyrx Increase Decrease In Deposits And Other Current Assets
IncreaseDecreaseInDepositsAndOtherCurrentAssets
45022 USD
cyrx Fair Value Of Warrants Issued Notes Payable
FairValueOfWarrantsIssuedNotesPayable
0 USD
cyrx Fair Value Of Warrants Issued Notes Payable
FairValueOfWarrantsIssuedNotesPayable
312680 USD
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
98100 USD
CY2015Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
75100 USD
CY2015Q3 cyrx Public Offering Units Issued Price Per Unit
PublicOfferingUnitsIssuedPricePerUnit
3.25
CY2015Q4 cyrx Lease Expiration Period
LeaseExpirationPeriod
commences on the substantial completion of the improvements thereon which we expect to be completed in February 2016 and expires seven years after such date, subject to our option to extend the lease for two additional five-year periods.
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2018-03-31

Files In Submission

Name View Source Status
0001144204-16-080857-index-headers.html Edgar Link pending
0001144204-16-080857-index.html Edgar Link pending
0001144204-16-080857.txt Edgar Link pending
0001144204-16-080857-xbrl.zip Edgar Link pending
cyrx-20151231.xml Edgar Link completed
cyrx-20151231.xsd Edgar Link pending
cyrx-20151231_cal.xml Edgar Link unprocessable
cyrx-20151231_def.xml Edgar Link unprocessable
cyrx-20151231_lab.xml Edgar Link unprocessable
cyrx-20151231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tlogo.jpg Edgar Link pending
v430854_10q.htm Edgar Link pending
v430854_ex31-1.htm Edgar Link pending
v430854_ex31-2.htm Edgar Link pending
v430854_ex32-1.htm Edgar Link pending